Clinical trial · Interventional
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation
Effects of a Pneumatic Compression Device in Post-Chemoradiation Head and Neck Cancer Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI retired and study not moving forward
Summary
Brief summary (as posted)
This clinical trial tests whether adding the use of a pneumatic compression system with manual lymphatic drainage versus manual lymphatic drainage alone in treating patients with lymphedema after chemoradiation for stage II-IV head and neck cancer. Lymphedema can be the result of surgery, radiation therapy, chemotherapy or any combination of these procedures. Internal lymphedema has been shown to negatively affect speech production, swallowing, respiration, and voice. Flexitouch is an advanced pneumatic compression device (APCD) that consists of a 2-piece garment that provides pressure changes to move lymph fluid from the impaired area toward healthy regions of the body. Complete decongestive therapy (CDT) is standard of care for treating external lymphedema and involves manual lymphatic drainage (MLD) performed by licensed therapists followed by compression therapy. CDT has long been used for treating lymphedema of the limbs. Combining a pneumatic compression system with standard of care manual lymphatic drainage may have positive effects on speech, voice, and swallowing.
Conditions
Conditions (16)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Clinical Stage II HPV-Mediated (p16-pos) Oropharyngeal Carcinoma | — | UNRESOLVED | — |
| Clinical Stage III HPV-Mediated (p16-pos) Oropharyngeal Carcinoma | — | UNRESOLVED | — |
| Clinical Stage IV HPV-Mediated (p16-pos)Oropharyngeal Carcinoma | — | UNRESOLVED | — |
| Head and Neck Carcinoma | Head and Neck Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Stage II Hypopharyngeal Carcinoma AJCC v8 | Hypopharyngeal Carcinoma | CURATED_BROADER | 0.78 |
| Stage III Hypopharyngeal Carcinoma AJCC v8 | Hypopharyngeal Carcinoma | CURATED_BROADER | 0.78 |
| Stage III Laryngeal Cancer AJCC v8 | Malignant Laryngeal Neoplasm | CURATED_BROADER |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Best Practice | Other | — | UNRESOLVED |
| Consensus Auditory-Perceptual Evaluation of Voice | Other | — | UNRESOLVED |
| Diagnostic Imaging | Procedure | — | UNRESOLVED |
| Lymphedema Management | Other | — | UNRESOLVED |
| Modified Barium Swallow | Procedure | — | UNRESOLVED |
| Nasopharyngeal Laryngoscopy | Procedure | — | UNRESOLVED |
| Pneumatic Compression Therapy | Device | — | UNRESOLVED |
| Quality-of-Life Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group I (pneumatic therapy, lymphedema management)
- description
- Patients undergo 32 minute treatments twice daily for 12 weeks using the FlexiTouch Plus System and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
- interventionNames
- Other: Consensus Auditory-Perceptual Evaluation of Voice
- Procedure: Diagnostic Imaging
- Other: Lymphedema Management
- Procedure: Modified Barium Swallow
- Procedure: Nasopharyngeal Laryngoscopy
- Device: Pneumatic Compression Therapy
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Other: Voice Handicap Index-10
- type
- ACTIVE_COMPARATOR
- label
- Group II (standard of care, lymphedema management)
- description
- Patients undergo standard of care self-manual lymphatic drainage (technique instructions provided) twice daily for 12 weeks and treatment with a lymphedema therapist weekly on weeks 2-11. Patients undergo nasolaryngoscopy and videofluoroscopic swallow study at baseline.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Completed definitive chemoradiation for Stage II or greater, histologically proven cancer of the oral cavity, oropharynx, hypopharynx, pharynx or larynx with a curative intent * Cognitive function adequate to understand and execute the elements of the protocol * Willingness and ability to return to Mayo Clinic for follow-up care per protocol * Resolution of acute dermatitis (skin must be intact without evidence of inflammation, infection or desquamation) as a result of chemoradiotherapy (CRT) * Must demonstrate oropharyngeal competency that would allow some oral intake Exclusion Criteria: * Prior surgery, radiation, chemotherapy, or immunotherapy for head or neck cancer * Acute radiation dermatitis, unhealed surgical wounds or surgical flap less than 2 months post-operative * Acute facial infection * Active congestive heart failure (CHF) or pulmonary edema * Symptomatic carotid artery disease or bradycardia * Increased intracranial pressure * History of multiple cerebrovascular accidents (CVAs) or transient ischemic attacks (TIAs) * \> 50% internal carotid artery (ICA) blockage * Upper quadrant deep vein thrombosis * Known esophageal obstruction * Percutaneous endoscopic gastrostomy (PEG) tube dependence with no oral intake * Women of child-bearing potential * (Active) pregnancy
References
Publications (0)
Data not yet available